MDinsight provides gastroenterology
practices with tools that enhance the clinical and research
value of their patient medical information
San Francisco,
CA, May 20, 2002 --- MDdatacor, inc., an Atlanta-based
medical informatics company, today announced the gastroenterology
market introduction of MDinsight, its physician
practice-based informatics solution. DIANON Systems
(NASDAQ:DIAN), a national provider of cancer and genomic
diagnostic services, has exclusive distribution rights
for MDinsight in the gastroenterology specialty. Dianon
is introducing the product at this week's Digestive
Disease Week meeting (Booth # 1047).
MDinsight utilizes a patented process
that converts previously non-searchable medical information
in the physician practice into a clinical database that
can be mined using its proprietary search technology.
Results of these searches are presented back to the
practice via secure Internet connection and provide
them with decision support tools that improve clinical
outcomes and enhance the practice's clinical research
capabilities.
Martin Stefanelli, senior vice president, Sales, Marketing
and Business Development for DIANON Systems, commented,
"We believe MDinsight will enhance DIANON's pathology
services by integrating our diagnostic results with
other clinically relevant patient information, enabling
the physician to more effectively assess the clinical
utility of various treatment modalities and their impact
on patient outcomes."
As a remotely delivered service, MDinsight
does not require the practice to purchase, install or
maintain expensive software, nor will it change the
practice's normal workflow. Practices need only Internet
access and electronic copies of patient medical information
to be able to fully benefit from this service.
David Finkelman, MD, chief executive
officer of Digestive Care Associates, an Atlanta-based
gastroenterology practice commented, "As one of
the first practices to use MDinsight, we have already
seen how this exciting technology improves our ability
to recruit patients into clinical trials."
|